Roche Molecular Diagnostics, the global market leader, develops diagnostic and blood screening tests and automated platforms based on its Nobel Prize-winning PCR technology. Results from the company's highly sensitive and standardized tests are used worldwide to improve blood safety, diagnose disease, monitor disease progression and response to therapy, as well as to identify gene-based factors that can aid treatment selection.

Roche Molecular Diagnostics is a business of Roche, which employs roughly 70,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. For further information about Roche Molecular Diagnostics, please visit our website.